Studies of Alzheimer's disease (AD) have predominantly focused on two major pathologies: amyloid-b (Ab) and hyperphosphorylated tau. These misfolded proteins can accumulate asymptomatically in distinct regions over decades. However, significant Ab accumulation can be seen in individuals who do not develop dementia, and tau pathology limited to the transentorhinal cortex, which can appear early in adulthood, is usually clinically silent. Thus, an interaction between these pathologies appears to be necessary to initiate and propel disease forward to widespread circuits. Recent multidisciplinary findings strongly suggest that the third factor required for disease progression is an aberrant microglial immune response. This response may initially be beneficial; however, a maladaptive microglial response eventually develops, fueling a feedforward spread of tau and Ab pathology.
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The Pathogenesis of AD
AD is the most common neurodegenerative disease, doubling every 5 years after the age of 65 and affecting one-third of those above the age of 85. Its prevalence is expected to triple by 2050 as a result of an expanding aging demographic [1] . Recent studies indicate that the preclinical development of AD begins years to decades before onset of memory deficits [2] . Over this timeframe, the two pathological hallmarks of Ab accumulation and tau (microtubule associated protein tau/MAPT) phosphorylation proceed asymptomatically, and are well underway by the time of initial diagnosis. Once predictive biomarkers for AD risk are identified, this preclinical phase will become a critical time-window in which to intervene preventively to delay progression to AD. Later interventions at the stage of dementia are less likely to be disease-modifying because there is already extensive loss of neurons and circuitry at this point.
The 'amyloid cascade hypothesis' of AD causation posits that accumulating Ab 42 peptides in the brain lead to hyperphosphorylation of tau and neurofibrillary tangles (NFTs), neuronal loss, and cognitive decline [3] . Since this initial hypothesis, neuropathological studies examining the temporal dynamics and anatomic distribution of amyloid and tau pathologies have expanded our understanding of the pathogenesis of AD (Figure 1 
Trends
The preclinical course of AD spans years to decades before the onset of cognitive decline. Early appearance of Ab 42 and tau pathologies are initially clinically silent and do not overlap anatomically. With progression to AD, these pathologies converge and spread from hippocampus to connected circuits.
Microglia play crucial roles in maintaining homeostasis in brain by clearing misfolded proteins and controlling inflammation.
GWAS and systems-biology approaches have identified the microglial immune response as a dominant factor in AD risk. Studies in AD model mice demonstrate that healthy microglial functions are lost with progression of amyloid pathology.
A maladaptive microglial immune response may be the precipitating factor underlying the escalation of pathology to AD.
Reprogramming microglia to more healthy states is a potential therapeutic direction.
